The ASPIRE trial showed a 73% reduction in healthcare consumption events with SURE compared to URS over two years. The CVAC System demonstrated high stone clearance and low residual stone volume in ...

Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.

The biomarker panel demonstrated the ability to detect prostate cancer even in men with prostate-specific antigen levels in the normal range.

Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.

"Liquid biopsy analysis provides a noninvasive and facile tool for early detection, diagnosis, and recurrence surveillance of urological cancer," writes Jim Lu, MD, PhD.

AB001 is a novel PSMA-targeted radioligand therapy designed to treat metastatic prostate cancer with potentially higher tumor dose rates and lower normal tissue toxicity. The phase 1 trial will enroll ...

The episode also underscores the role of artificial intelligence in prostate imaging. In this episode of Pearls & Perspectives, Amy Pearlman, MD, speaks with Dan Sperling, MD, DABR, a board-certified ...

Inlexzo, a gemcitabine intravesical system, is approved for BCG-unresponsive NMIBC, offering extended local drug delivery for up to 14 cycles. The SunRISe-1 trial showed an 82.4% complete response ...

William C. Huang, MD, highlights data from a long-term extension study of the OPTIMA II trial. In a recent interview with Urology Times®, William C. Huang, MD, outlined the key findings and ...

IDE397 combined with sacituzumab govitecan showed promising efficacy in MTAP-deletion urothelial carcinoma, with high disease control rates in both dose cohorts. The combination therapy's efficacy ...

The combination of olaparib and radium-223 improved rPFS in CRPC patients with bone metastases compared to radium-223 alone. The greatest benefit was observed in patients without prior docetaxel ...

Combining BCG with ICIs targets the PD-1/PD-L1 pathway to overcome BCG resistance in NMIBC. The CREST trial showed improved event-free survival with BCG plus sasanlimab compared to BCG alone. Future ...